jili games gcash real money

jili games gcash real money Quant Trading Society Launches QTS Investor Pro, Democratizing Algorithmic Trading for Retail Investors 12-20-2024 12:22 AM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire Quant Trading Society (QTS) [ https://www.quanttradingsociety.com/ ], a pioneering quant trading company, is transforming the financial landscape for busy professionals seeking efficient investment solutions. Through its newly launched QTS Investor Pro program, the firm is making algorithmic trading-once exclusive to hedge funds-accessible to retail investors. With over two years of development and a proven track record, QTS aims to bridge the gap between traditional investment strategies and cutting-edge trading technology. "Automation can be an intimidating concept for many investors," says Moayad Sallabi, Founder of Quant Trading Society. "Our mission is to make this advanced technology approachable, reliable, and profitable for everyone, regardless of their financial background or trading experience." QTS Investor Pro offers a comprehensive and guided experience for participants, granting them access to the firm's proprietary trading algorithms. Unlike traditional strategies limited to bonds, stocks, or real estate, the QTS system operates with a unique mechanism called the Dynamic Optimization Protocol. This protocol employs rigorous criteria to determine when and how the algorithms engage with the market, minimizing risk and ensuring consistent performance. "Dynamic Optimization is a game-changer for retail investors," explains Moayad Sallabi. "It's this innovation that sets us apart from competitors and delivers the reliability that investors demand." Since its launch, the QTS Investor Pro program has garnered significant attention, attracting over 950 users. The platform boasts an impressive rating, highlighting its effectiveness and ease of use. For added reassurance, QTS offers a 30-day money-back guarantee, ensuring clients can test the platform risk-free. One satisfied user shared, "I never imagined automated trading could be this simple. It's like having a hedge fund's capabilities in my back pocket." Algorithmic trading has long been the domain of institutional investors and hedge funds. QTS's initiative marks a pivotal moment in democratizing this sophisticated tool for everyday investors. By removing the time and effort traditionally associated with trading, the platform allows users to reap the benefits of advanced market strategies while focusing on their professional lives. Quant Trading Society envisions a financial future where automation is no longer a daunting prospect but a trusted ally for investors. The QTS Investor Pro program emphasizes a market-neutral approach, empowering participants to explore diverse financial opportunities beyond conventional assets. Applications are now open for those interested in exploring this innovative platform. Licensing opportunities are available through the Quant Trading Society website at http://www.quanttradingsociety.com , and prospective users can learn more about the company's journey and expertise via their Instagram @quanttradingsociety [ https://www.instagram.com/quanttradingsociety ]. About Company: Quant Trading Society (QTS) is a leading quant trading company headquartered in Cork, Ireland. The firm specializes in making algorithmic trading accessible to retail investors, empowering them with innovative tools to achieve consistent returns. QTS is dedicated to simplifying automation and bridging the gap between traditional investments and advanced trading strategies. Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. Media Contact Company Name: Quant Trading Society Contact Person: Moayad Sallabi Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=quant-trading-society-launches-qts-investor-pro-democratizing-algorithmic-trading-for-retail-investors ] City: Dublin Country: Ireland Website: http://www.quanttradingsociety.com This release was published on openPR.On December 6, 2024, Principal Associate Deputy Attorney General Marshall Miller provided an update on the Justice Department’s (DOJ) corporate criminal enforcement efforts during his keynote address at the Practicing Law Institute’s White Collar Crime 2024 Program . Among other topics, Miller addressed ongoing efforts to combat corporate crime using self-disclosure policies and whistleblower programs when he said, “We’ve given good actors more avenues to help us go after the bad guys – through innovative whistleblower programs and consistent, transparent, and predictable voluntary self-disclosure policies. And we’ve made clearer than ever before what we expect from companies cooperating with government investigations to accelerate investigations of wrongdoers.” In the speech , Miller touted the DOJ’s recent successes securing convictions of numerous individuals, including “the CEOs of the world’s two largest cryptocurrency platforms – FTX and Binance; the CEO and COO of Theranos; the founder and the CFO of Archegos; two senior executives of Goldman Sachs; and dozens of other high-ranking executives across a range of industries.” In addition, Miller reiterated the continuing focus on whistleblowers and voluntary self-disclosure policies, asserting that the DOJ had “clarified the rules of the road” on those topics. Miller highlighted the similarities between voluntary self-disclosure policies and whistleblower programs, noting “for the first time as of August 2024, DOJ has instituted a Department-led whistleblower program with clear incentives for dropping a dime on corporate crime.” We previously detailed the new DOJ whistleblower reward program here . That program is designed to focus on four subject matter areas: 1) violations by financial institutions, their insiders and agents involving money laundering, fraud, and fraud against or non-compliance with regulators; 2) foreign corruption and bribery and violations of money laundering statutes; 3) domestic corruption violations including bribes and kickbacks paid to domestic public officials; and 4) healthcare offenses involving private or non-public healthcare benefit programs and fraud against patients, investors or other non-governmental entities in the healthcare industry, or other violations of federal law not covered by the federal False Claims Act. In his speech, Miller noted that whistleblower programs do not exist in a vacuum – “[r]ather, they fill in the gaps and build on effective existing models employed in SEC, CFTC, FinCen and False Claims Act cases.” A full understanding and effective application of the new whistleblower reward program may increase a company’s chances of avoiding a guilty plea or indictment. Under the program “a voluntary self-disclosure to the Criminal Division can also qualify a company for the presumption of a declination of prosecution.” Miller emphasized the “significant results” the program has yielded, including steady increases in voluntary self-disclosures – in fact, last year’s numbers doubled those from 2021. Miller also pointed to the DOJ’s receipt of over 250 whistleblower tips, “many which appear to identify criminal conduct we didn’t know about.” Miller also referenced a U.S. Attorneys’ Offices report that individual voluntary self-disclosures have resulted in “promising ongoing investigations,” but did not provide details regarding the number or nature of such cases. Miller also discussed recent updates to the DOJ’s guidance on evaluating corporate compliance programs. Although the DOJ’s guidance doesn’t tell companies how to design and implement their compliance programs, it identifies four questions the DOJ expects executives and board members to ask in assessing the compliance program’s efficacy: Have we empowered our compliance leaders and invested sufficiently in our compliance program, given our risk profile and today’s geopolitical landscape? Do we have effective internal detection and reporting systems and robust internal investigative capabilities, so we can avail ourselves of voluntary self-disclosure opportunities? Have we designed compensation systems that promote compliance and enable clawbacks or escrowing of incentive comp? Have we assessed risks associated with national security and emerging technologies and taken appropriate steps to mitigate them? In Miller’s view, “if a company finds itself on the wrong side of a DOJ investigation tomorrow, the company’s posture may well depend on how its leadership answers those questions today.” While the above four questions are helpful to guide compliance program self-evaluations, self-disclosure determinations typically require a more holistic assessment. In that context, companies who identify potential violations must be able to swiftly gauge whether to self-disclose potential violations and, as part of that effort, assess whether to cooperate or otherwise act to accelerate the government’s investigation. Such decisions must be made quickly, underscoring the need for companies to have at least a framework in place before the fact, and to consult attorneys experienced in making self-disclosures and in working with the government throughout that process. In this context, determining which choice best aligns with the company’s interests is seldom a simple calculus. Listen to this post

NEW YORK (AP) — If anybody knows Deion Sanders' mind, it might be Travis Hunter. And the two-way Colorado star says Coach Prime is indeed staying put with the Buffaloes. “I got a lot of insight. He ain’t going nowhere. He’s going to be right where he's at right now,” Hunter said Friday in Manhattan, where he's a heavy favorite to win the Heisman Trophy on Saturday night. In his second season at the school, Sanders coached No. 20 Colorado to a 9-3 record this year and its first bowl bid since 2020. Hunter, Sanders and the Buffaloes will face No. 17 BYU (10-2) in the Alamo Bowl on Dec. 28. Sanders' success and popularity in Boulder has led to speculation the flashy and outspoken former NFL star might seek or accept a coaching job elsewhere this offseason. Sanders, however, has dismissed such talk himself. Hunter followed Sanders from Jackson State, an HBCU that plays in the lower level FCS, to the Rocky Mountains and has already racked up a staggering string of individual accolades this week, including The Associated Press player of the year. The junior wide receiver and cornerback plans to enter the 2025 NFL draft and is expected to be a top-five pick — perhaps even No. 1 overall. But he backed up assertions from Sanders and his son, star Colorado quarterback Shedeur Sanders, that both will play in the Alamo Bowl rather than skip the game to prepare for the draft and prevent any possible injury. “It's definitely important because, you know, I started this thing with Coach Prime and Shedeur and most of the coaches on the coaching staff, so I want to finish it off right,” Hunter said. "I didn't give them a full season my first year (because of injury), so I'm going to go ahead and end this thing off right. It's going to be our last game together, so I'm going to go out there and dominate and show the loyalty that I have for him. “Definitely looking forward to it. I'm just excited to go out there and play football one more time before the offseason.” Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballJaland Lowe, Pitt charge past LSU in second half to move to 6-0Score $100 Off the Beats Solo 4, and Tune Into Premium Sound

Ayar Labs captures $155M to bring light into chip manufacturingMilestone at Hydrogen Dialogue – KEYOU hands over first 18t truck to pioneer customer EP Trans The integration work for the first pioneer vehicles was carried out by KEYOU’s long-term partner Paul Nutzfahrzeuge in Vilshofen near Passau. The commercial vehicle experts were already responsible for the construction of the two KEYOU prototype vehicles – the 12-meter city bus and the 18-ton truck, which served as blueprint for the now completed pioneer vehicles. The 18-ton trucks, based on a Daimler Actros chassis and equipped with a converted 7.8-liter Deutz engine with KEYOU-inside system and a fully automatic transmission from Allison Transmission, were recently handed over to the Munich-based hydrogen experts. After some tests and final optimizations, the vehicle will soon receive its road approval. The first vehicle was officially handed over to pioneering customer EP Trans at this year’s Hydrogen Dialogue in Nuremberg. The delivery was originally scheduled for the end of 2023, but has been postponed several times due to delivery problems of a key component supplier. Bavaria’s Minister of Economic Affairs, Regional Development and Energy, Hubert Aiwanger, was on site to officially witness the handover and congratulate everyone involved on this important milestone. The KEYOU H2 truck is an important step in the decarbonization of EP Trans’ truck fleet and the supply chain of its end customers. The planned route is still being finalized, but the logistics company is expected to operate the truck in Bavaria for an international steel company, benefiting from the many advantages of the technology. Managing Director of EP Trans, says : also Managing Director of EP Trans, says : “The fact that KEYOU’s offer also allows us to save on the CO2 toll and that the all-inclusive package means we don’t have to worry about issues such as insurance or vehicle service and maintenance is an added bonus. The delays were of course a pity for us as well, but we are all the more pleased that we will soon be able to start,” The advantages of the hydrogen engine over other propulsion technologies become even more apparent over long distances and therefore in the heavy-duty segment. In order to fully exploit this potential, KEYOU has initiated a strategic realignment with its appearance at this year’s IAA and, following the successful market launch of its pioneering 18-ton fleet, will focus entirely on the development and introduction of its 40-ton offering. The first Actros-based 40-ton trucks with KEYOU-inside hydrogen engines are expected to roll off the production line in 2026. The model KEYOU is currently working on is based on a Daimler Actros with a 12.8-liter engine and will have an output of 346 kW. As with the 18-ton truck, hydrogen tanks with a pressure of 350 bar will be installed. It is expected that the planned tank volume will allow for a range of approximately 650 kilometers. The company announced the official sales start at the end of November with a limited sales offer. the latest news shaping the hydrogen market at Milestone at Hydrogen Dialogue – KEYOU hands over first 18t truck to pioneer customer EP Trans, California approves $1,4 billion plan to build thousands more vehicle chargers, boost ZEV infrastructure – electric charging and hydrogen refueling stations SACRAMENTO – Thousands more electric vehicle (EV)... Next Hydrogen Solutions Inc Announces Closing of Private Placement of Unsecured Convertible Debentures MISSISSAUGA, Ontario, Dec. 13, 2024 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (TSXV: NXH, OTC: NXHSF)... Everfuel and Karlstads Energi gets funding notification for potential project in Sweden Herning, Denmark, 13 December 2024 – Everfuel A/S’ is pleased to announce that its subsidiary Everfuel Production Karlstad AB...

Mumbai Consumer Commission Secures ₹2.15 Lakh Compensation From Defiant Travel Firms After Police Intervention

MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates. About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com . Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor Contact Louisa Smith [email protected]Unwrap the latest AI features with Amazon Fire Tablets( MENAFN - GetNews) "C5ISR Market"The C5ISR market is projected to reach USD 19,280.8 million by 2029, from USD 10,720.1 million in 2024, at a CAGR of 12.5%. The report " C5ISR Market by Solution (Hardware, Software, and Services), End User (Army, Navy, Airforce, and government & Law Enforcement), Installation (New Installations, and Upgrades) and Region - Global Forecast to 2029 " The C5ISR market is projected to reach USD 19,280.8 million by 2029, from USD 10,720.1 million in 2024, at a CAGR of 12.5%. The growth of the C5ISR market is driven by several factors, including evolving cybersecurity threats. Download PDF Brochure @ Browse 233 market data Tables and 77 Figures spread through 340 Pages and in-depth TOC on "C5ISR Market" View detailed Table of Content here - In the defense sector, C5ISR technologies are transforming operational effectiveness by enhancing situational awareness, decision-making, and mission execution. Modern militaries are increasingly relying on integrated C5ISR systems for seamless communication, robust cybersecurity, and real-time intelligence across various domains. The growing complexity of global security challenges is driving defense organizations to invest in resilient, adaptable, and technologically advanced C5ISR systems. As nations strive to maintain a tactical edge in modern warfare, the demand for innovative C5ISR capabilities continues to grow, underpinned by significant government funding and a focus on next-generation defense strategies. Based on end user, the army segment is dominating the C5ISR market from 2024 to 2029 As the army has a wide operational scope and reliance on integrated systems for land-based missions, this segment is leading the C5ISR market based on end users. For mission-critical tasks like battlefield awareness, real-time command and control, secure communications, and intelligence collection, armies need sophisticated C5ISR capabilities. In complex and dynamic situations, these talents are essential for maintaining operational effectiveness. The army segment's supremacy is also fueled by rising investments in updating ground troops with technology like cyber defense, unmanned ground vehicles, and electronic warfare systems. The need for complete C5ISR solutions is still at the forefront of the market since land forces continue to play a key role in military operations across the globe. Based on installation, the new installation segment is estimated to dominate the market from 2024 to 2029 As defense forces throughout the world are adopting more sophisticated and upgraded systems, the new installation segment is anticipated to dominate the C5ISR market based on installation. Armed forces are making significant investments in cutting-edge C5ISR technology as they concentrate more on improving their ability to counter new threats like cyberattacks and multi-domain warfare. Advanced technologies that cannot always be effortlessly retrofitted into older systems, such as artificial intelligence (AI), big data analytics, and autonomous systems, require new installations. Additionally, this sector has grown to be the largest in the market due to modernization initiatives in emerging economies and the requirement for new infrastructure to support cutting-edge technology. North America is expected to capture the largest share during the forecast period in 2024. Because of the North American region's strong defense spending, especially from the US, which makes up the greatest portion of global military spending, North America has the largest market share in the C5ISR industry. To keep up its technological advantage in multi-domain operations, such as land, air, sea, space, and cyber warfare globally, the US Department of Defense (DoD) is making significant investments in cutting-edge C5ISR technologies. Major C5ISR companies that foster innovation and provide state-of-the-art solutions, such Lockheed Martin Corporation (US), Northrop Grumman Corporation (US), General Dynamics Corporation (US), and RTX Corporation (US), are also based in the region. The emphasis on updating military hardware, the expanding use of artificial intelligence and cyber defenses, and the growing demand for integrated solutions to further combat new threats The major players in the region include General Dynamics Corporation (US), Leidos (US), Lockheed Martin Corporation (US), CACI International Inc. (US), Airbus (France), Northrop Grumman (US), Lockheed Martin Corporation (US), and L3harris Technologies Inc. MENAFN19122024003238003268ID1109014551 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

The undefeated Vernon Panthers will look to ground some northern birds in the semifinals at the 2024 Tsumura Basketball Invitational Girls High School Basketball tournament in the Fraser Valley. The Panthers will face the Duchess Park Condors of Prince George at 4:30 p.m. Friday, Dec. 13. Dave Tetreault's crew advanced to the Select 16 semifinals by freezing the South Delta Sun Devils 63-54 in a Thursday quarterfinal. The Sun Devils led 14-1 before the Panthers got going, tying the game at the half, then taking their own 13-point lead late in the third quarter. But South Delta clawed back to pull ahead 54-52, only to see the Panthers end the game on an 11-0 run. Paige Leahy led VSS with 19 points, Chloe Collins added 15, and Adie Janke had 14. Collins and Janke nailed key three-point shots in the final quarter for the Cats. The Panthers will next face the smothering defence of the Condors, who defeated Langley's Walnut Grove Gators 88-27 in their quarterfinal. Duchess Park held the Gators to just 11 first-half points. In the Super 16 bracket, the Kelowna Owls were bounced from the championship side, falling 62-56 to Langley's Brookswood Bobcats. The Owls held Grade 10 phee-nom Jordyn Nohn to just 17 points. Nohr erupted for 52 points in the Bobcats' opening round game. Mavleen Chahal led the Owls with 25 points while Ava Thiessen scored all 12 of her points from the three-point line. On the consolation side, the Okanagan Mission Huskies of Kelowna evened their tournament record at 1-1 with a 56-50 win over the Sa-Hali Sabres of Kamloops. The Huskies face the Semiahmoo Thunderbirds of Surrey at 11:45 a.m. The Owls will take on the Lord Tweedsmuir Panthers of Surrey at 4:30 p.m. For schedule and scores, .

SpaceX's Power Outage Sparks Controversy and Future ConcernsWomen make up 35 percent of STEM positions across the world, according to the National Center for Science and Engineering . During the Reimagining Opportunities to Achieve and Rise (ROAR) event at the Sarah Heinz House on the North Side on Wednesday, young girls were given the chance to see firsthand what a career in science, technology, engineering and mathematics, or STEM, could look like. “We wanted the young girls to understand the opportunities available to them, it’s OK if they don’t decide to be in STEAM, but I want that to be their choice,” said Demeshia Seals, CEO of Sarah Heinz House , a non-profit that provides support to youth through programming to uplift, empower and help them reach their full potential (STEAM is science, technology, engineering, arts and mathematics). “I am firmly entrenched in the notion that it is hard to be what you can’t see,” Seals said. “The sky is the limit and they can do whatever they decide.” Around 200 young girls participated in the annual event from schools across the city. The day featured several workshops, including amazing aqueducts with Alcosan, AI text generation with Howmet Aerospace, a robotics academy and human-computer interaction with Carnegie Mellon University and heart-pumping research with the University of Pittsburgh Heart Lab. “This day is so important because we need more diversity both within people of color and in women in STEM. We get to do that by having our young people come and get to try out things that they might not have tried out in other places. We can do it together in a safe space, and not feel intimated, but feel confident in doing so,” said Christine Nguyen, STEAM director at Sarah Heinz House. “Today was an opportunity to provide knowledge to the girls so that we could leave the door open for them,” said ROAR alum Paige Frank, 19, who co-led the AI text generation workshop. Frank attends the University of Pittsburgh and interned at Amazon in Seattle this past summer. “I think a huge part of being a girl in STEM is getting past the ‘I’m not good enough’ mentality. I think today was giving them the confidence and equipping them with the knowledge so that they can walk in rooms and know that they do belong there,” Frank said. During the event, the young girls were encouraged to give each other one meaningful compliment to promote women’s empowerment. The day concluded with a panel discussion featuring four women in the STEM field: Ashley Petrouski from Howmet Aerospace, Kenya Sheppard Porter from Google, RyKai Wright from MSA Safety and Parva Markiw from Design Group. The theme of their discussion was centered around confidence, curiosity and critical thinking. During the panel, Porter shared an impactful message with the young girls: “Anytime you hear someone tell you no, if you want it bad enough you can get it. Don’t allow the negative storytelling of others to create fear inside of you so that you don’t move forward, let it drive you and make you hungry and bring you to success. “Giving back is something that I will always do, being a Black woman in tech and in STEM it is important for me to be the light to shine the way and provide the pathway for girls and other people who look like me to get into this field,” Porter said. “To help them provide them sustainability for themselves and their family. As Wright was pursuing mechanical engineering, she was told that she was a double negative because she is a woman and a woman of color. “If you know math, you know that a negative times a negative makes a positive. It’s important to just keep pushing forward despite what others think,” Wright said. “The biggest thing is encouragement, so being able to be a role model is amazing, expressing to the girls that you can do really well in this field.” Markiw, an Iranian native who came to the United States 20 years ago, became interested in architecture accidentally. She was at the house of a friend whose mother was an architect. The heated floors in their house got her curious. “When I went through architecture school, there were not a lot of minorities in the room,” Markiw said. “A lot of schooling looked like males and white counterparts. I want to make sure that I do get involved with these events, just to invite students who may have never heard of architecture as a career — I learned about it by accident. I want to make sure these students have that awareness.”

Phoenix Suns @ Utah Jazz Current Records: Phoenix 12-11, Utah 5-18 When: Friday, December 13, 2024 at 9:30 p.m. ET Where: Delta Center -- Salt Lake City, Utah TV: Arizona Family Sports Network Follow: CBS Sports App Online streaming: fuboTV (Try for free. Regional restrictions may apply.) Ticket Cost: $7.00 The Suns are 8-2 against the Jazz since February of 2022, and they'll have a chance to extend that success on Friday. The Phoenix Suns are set to face off against the Utah Jazz at 9:30 p.m. ET at Delta Center with a little bit of extra rest. The Suns are no doubt hoping to put an end to a six-game streak of away losses. Last Sunday, the Suns were within striking distance but couldn't close the gap as they fell 115-110 to the Magic. Phoenix got off to an early lead (up 12 with 2:42 left in the first quarter), but sadly they weren't able to maintain that momentum. Meanwhile, after soaring to 141 points the game before, the Jazz faltered in their contest on Sunday. They were dealt a punishing 141-97 defeat at the hands of the Kings. The loss unfortunately continues a disappointing trend for Utah in their matchups with Sacramento: they've now lost seven in a row. The Jazz's defeat came about despite a quality game from Keyonte George, who went 8 for 14 en route to 25 points plus six assists and five rebounds. George is trending in the right direction considering he's improved his point production for four straight games. Less helpful for the Jazz was Svi Mykhailiuk's abysmal 0-5 three-point shooting. Phoenix's loss dropped their record down to 12-11. As for Utah, their defeat dropped their record down to 5-18. Looking ahead, the Suns are the favorite in this one, as the experts expect to see them win by eight points. For those looking to play the spread, take note: they are a solid 8-5 against the spread when expected to win. The Suns beat the Jazz 120-112 in their previous matchup back in November. Do the Suns have another victory up their sleeve, or will the Jazz turn the tables on them? We'll have the answer soon enough. Phoenix is a big 8-point favorite against Utah, according to the latest NBA odds . The line on this game has moved quite a bit since it opened, as it started out with the Suns as a 5-point favorite. The over/under is 231.5 points. See NBA picks for every single game, including this one, from SportsLine's advanced computer model. Get picks now . Phoenix has won 8 out of their last 10 games against Utah. Nov 12, 2024 - Phoenix 120 vs. Utah 112 Feb 08, 2024 - Phoenix 129 vs. Utah 115 Nov 19, 2023 - Phoenix 140 vs. Utah 137 Nov 17, 2023 - Phoenix 131 vs. Utah 128 Oct 28, 2023 - Phoenix 126 vs. Utah 104 Mar 27, 2023 - Phoenix 117 vs. Utah 103 Nov 26, 2022 - Phoenix 113 vs. Utah 112 Nov 18, 2022 - Utah 134 vs. Phoenix 133 Apr 08, 2022 - Phoenix 111 vs. Utah 105 Feb 27, 2022 - Utah 118 vs. Phoenix 114

JAMAICA, N.Y. , Dec. 13, 2024 /PRNewswire/ -- The New Terminal One at John F. Kennedy International Airport (JFK) today announced that Turkish Airlines will begin operations at the new terminal when it opens in 2026. Turkish Airlines will also unveil a brand new, state-of-the-art lounge for its premium customers, launching the next phase of the award-winning airline's growth at its top U.S. gateway. The New Terminal One, set to be the largest international terminal in the United States , will offer best-in-class amenities and innovative technology for a transformational and efficient travel experience. The New Terminal One is a key component of the Port Authority of New York and New Jersey's $19 billion transformation of JFK Airport into a world-class gateway, which will include two new terminals, the modernization and expansion of two existing terminals, a new ground transportation center, and an entirely new, simplified roadway network. Turkish Airlines, which currently flies 19 times weekly from JFK Airport to its hub at Istanbul , providing seamless connections to its extensive global network, will continue to offer top-tier service from the new terminal. As part of its expansion in the JFK market, Turkish Airlines will open an 11,000-square-foot lounge in the New Terminal One – twice the size of the airline's lounge at the existing Terminal 1. The new lounge will feature premium amenities, expansive views of JFK Airport's airfield and provide direct boarding access to aircraft, offering unmatched convenience for Turkish Airlines' business class customers and top-tier frequent flyers. Recognized for its exceptional in-flight service, Turkish Airlines recently received the World Class Award from the Airline Passenger Experience Association (APEX) for the fourth consecutive year, placing it among just 10 airlines in the world to have received this prestigious recognition. Turkish Airlines was also chosen as the Best Airline in Europe nine times by Skytrax. Over the years Turkish Airlines also received accolades from Skytrax and other prestigious organizations numerous times for its Business and Economy Class offerings and Lounges. Turkish Airlines offers service to 351 destinations, including 25 in the Americas. Turkish is a member of the Star Alliance and will join other alliance members at the New Terminal One: LOT Polish Airlines, EVA Air and Air China. "We are thrilled to welcome Turkish Airlines to the New Terminal One at JFK, where their commitment to world-class customer service aligns perfectly with our mission to provide an unparalleled customer experience," said The New Terminal One Chief Executive Officer Jennifer Aument . "We look forward to working closely with our colleagues at Turkish Airlines to elevate the travel experience for customers from 2026 and beyond." Turkish Airlines Chairman of the Board and the Executive Committee Prof. Ahmet Bolat stated: "We are excited to bring Turkish Airlines' world-class service to the New Terminal One at JFK, further enhancing our passengers' travel experience with a state-of-the-art-lounge. This move underlines our commitment to continue our growth in the U.S market." In addition to Turkish Airlines, the New Terminal One has partnered with several other global carriers, including Air France, KLM, Etihad, LOT Polish Airlines, Korean Air, EVA Air, Air Serbia, SAS, Neos and Philippine Airlines. Air China is also partnering with the terminal on elevating the travel experience for Chinese customers visiting New York . The New Terminal One is focused on improving the customer experience by collaborating with potential airline partners. This includes working with airline teams across all customer journey touchpoints. Set to be JFK Airport's largest terminal when complete, the New Terminal One will offer a world-class customer experience and additional widebody aircraft gate capacity – providing international airlines a unique opportunity to grow their service at JFK, the top global gateway to the U.S. About The New Terminal One The New Terminal One at John F. Kennedy International Airport is a bold and exciting project to develop a world-class international terminal that will serve as an anchor terminal in the Port Authority's $19 billion transformation of JFK into a global gateway to the New York metropolitan area and the United States . The New Terminal One will set a new standard for design and service, aspiring to obtain a Top 5 Skytrax ranking and be considered one of the finest airport terminals in the world. The New Terminal One is being built on sites now occupied by Terminal 1 and the former Terminal 2 and Terminal 3, where it will anchor JFK's south side. Construction is taking place in phases. The first phase, including the new arrivals and departures halls and first set of 14 new gates, is expected to open in 2026. At completion, anticipated in 2030, the New Terminal One will be 2.6 million square feet, making it the largest terminal at JFK and nearly the same size as LaGuardia Airport's two new terminals combined. The New Terminal One will be a 23-gate, state-of-the-art, international-only terminal. Sustainably designed and future-focused, the terminal will feature expansive, naturally lit public spaces, cutting-edge technology, and an array of amenities, all designed to enhance the customer experience and compete with some of the highest-rated airport terminals in the world. The New Terminal One consortium of labor, operating, and financial partners is led by Ferrovial, JLC Infrastructure, Ullico, and Carlyle. The New Terminal One is being built by union labor and is committed to local inclusion and labor participation, focusing on diversity and capacity-building opportunities, including ambitious participation goals of 30% for minority and women-owned enterprises, 10% for local business enterprises and 3% for service-disabled veteran-owned businesses. To learn more about the New Terminal One at JFK International Airport, visit https://www.anewjfk.com/projects/the-new-terminal-one/ About Turkish Airlines Established in 1933 with a fleet of five aircraft, Star Alliance member Turkish Airlines has a fleet of 491 (passenger and cargo) aircraft flying to 351 worldwide destinations in 130 countries (298 international destinations and 53 domestic destinations within Turkiye). More information about Turkish Airlines can be found on its official website www.turkishairlines.com or its social media accounts on Facebook, X, YouTube, LinkedIn and Instagram. View original content to download multimedia: https://www.prnewswire.com/news-releases/turkish-airlines-to-begin-operations-at-the-new-terminal-one-at-jfk-and-unveil-world-class-lounge-302331710.html SOURCE The New Terminal One at JFKPercentages: FG .518, FT .909. 3-Point Goals: 6-19, .316 (Waddles 3-5, Sutton 2-6, Thomas 1-3, Glover 0-1, Osburn 0-1, White 0-3). Team Rebounds: 3. Team Turnovers: 1. Blocked Shots: None. Turnovers: 12 (Waddles 3, Glover 2, Sutton 2, White 2, Ondekane, Streit, Thomas). Steals: 3 (Glover, Sutton, White). Technical Fouls: None. Percentages: FG .530, FT .444. 3-Point Goals: 18-39, .462 (T.Johnson 4-7, Hardman 4-10, Lyles 3-6, Gray 2-3, N.Johnson 2-3, Harris 2-4, Young 1-1, Scott 0-2, S.Wilson 0-3). Team Rebounds: 4. Team Turnovers: None. Blocked Shots: 3 (Lyles 2, Okonkwo). Turnovers: 8 (T.Johnson 3, Scott 2, Gray, Lyles, Okonkwo). Steals: 7 (Lyles, N.Johnson, Okonkwo, S.Wilson, Scott, T.Johnson, Young). Technical Fouls: None. .

(BPT) - Tech gifts are consistently some of the most popular presents to give and receive during the holidays. In fact, according to the annual Consumer Technology Holiday Purchase Patterns report , a record 233 million U.S. adults (89%) will buy tech products during the 2024 holiday season. But with so many devices out there, it can be hard to decide on the perfect option for the loved one on your list. A tablet like the new Fire HD 8 from Amazon offers the versatility of an all-in-one device, with access to streaming, gaming, video chatting, reading or writing all at your fingertips. Fire HD 8 also features a vibrant 8-inch HD display and lightweight, portable design, for high-quality entertainment on the go. Plus, Fire HD 8 comes with three new AI features that can help you get the most out of your tablet experience. Check them out below and learn how they can help you with daily tasks this holiday season and beyond. 1. Meet your personal writing assistant Do you struggle with writing a heartfelt message or finessing a tricky email? Fear not! Writing Assist is here to help. Writing Assist works as part of your Fire tablet's device keyboard and compatible apps, including email, Word documents and social media. In just a few taps, you can transform your writing from good to great. Try Writing Assist's pre-set styles to turn a simple email into a professionally written note. Or, you can ask Writing Assist for grammar suggestions to make your writing more concise, or elaborate on your ideas. You can even "emojify" your writing to add more fun and personality. 2. Learn more in less time Say goodbye to scrolling through pages of information. The new Webpage Summaries feature allows you to learn pertinent information as quickly as possible. Available on the Silk browser on Fire tablets, Webpage Summaries provides quick insights on web articles. In a matter of seconds, this feature will distill the key points in an article or on a webpage into a clear, concise summary of what you need to know. 3. Get creative with your device wallpaper With Wallpaper Creator, you can easily add a touch of creative flair and customization to your tablet's home screen. You can choose from one of the curated prompts to get started on creating a unique background. Or, if you're ready to let your imagination run wild, type a description of what you'd like to see. For example, you can ask for an image of a tiger swimming underwater or a watercolor-style image of a desert landscape in space. Wallpaper Creator will then turn your vision into a reality, delivering a high-resolution image that you can use as your tablet's wallpaper. Celebrate an AI-powered holiday season Writing Assist, Webpage Summaries, and Wallpaper Creator are now available on Amazon's new Fire HD 8 and other compatible Fire tablet devices, including the latest Fire HD 10 and Fire Max 11 tablets. To learn more, or to order a new Fire tablet this gift-giving season, visit Amazon.com .

By JILL COLVIN NEW YORK (AP) — President-elect Donald Trump wants to turn the lights out on daylight saving time. In a post on his social media site Friday, Trump said his party would try to end the practice when he returns to office. “The Republican Party will use its best efforts to eliminate Daylight Saving Time, which has a small but strong constituency, but shouldn’t! Daylight Saving Time is inconvenient, and very costly to our Nation,” he wrote. Setting clocks forward one hour in the spring and back an hour in the fall is intended to maximize daylight during summer months, but has long been subject to scrutiny. Daylight saving time was first adopted as a wartime measure in 1942. Lawmakers have occasionally proposed getting rid of the time change altogether. The most prominent recent attempt, a now-stalled bipartisan bill named the Sunshine Protection Act , had proposed making daylight saving time permanent. The measure was sponsored by Florida Sen. Marco Rubio , whom Trump has tapped to helm the State Department. Related Articles National Politics | Ruling by a conservative Supreme Court could help blue states resist Trump policies National Politics | A nonprofit leader, a social worker: Here are the stories of the people on Biden’s clemency list National Politics | Nancy Pelosi hospitalized after she ‘sustained an injury’ on official trip to Luxembourg National Politics | Veteran Daniel Penny, acquitted in NYC subway chokehold, will join Trump’s suite at football game National Politics | About 3 in 10 are highly confident in Trump on Cabinet, spending or military oversight: AP-NORC poll “Changing the clock twice a year is outdated and unnecessary,” Republican Sen. Rick Scott of Florida said as the Senate voted in favor of the measure. Health experts have said that lawmakers have it backward and that standard time should be made permanent. Some health groups , including the American Medical Association and American Academy of Sleep Medicine, have said that it’s time to do away with time switches and that sticking with standard time aligns better with the sun — and human biology. Most countries do not observe daylight saving time. For those that do, the date that clocks are changed varies, creating a complicated tapestry of changing time differences. Arizona and Hawaii don’t change their clocks at all.CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.